The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CNTX | +181.93% | N/A | N/A | -54% |
| S&P | +14.43% | +77.25% | +12.13% | +53% |
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
No news articles found for Context Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$4.07K | -44.6% |
| Market Cap | $86.91M | -40.9% |
| Market Cap / Employee | $7.24M | 0.0% |
| Employees | 12 | 0.0% |
| Net Income | -$9,693.24K | 44.5% |
| EBITDA | -$10,606.41K | 43.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $76.94M | -9.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $21.22K | -84.9% |
| Short Term Debt | $118.98K | 14.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -31.94% | 23.2% |
| Return On Invested Capital | -73.48% | -11.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6,578.86K | 60.6% |
| Operating Free Cash Flow | -$6,578.86K | -240.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.94 | 0.58 | 0.65 | 1.05 | -27.59% |
| Price to Tangible Book Value | 0.94 | 0.58 | 0.65 | 1.05 | -27.59% |
| Enterprise Value to EBITDA | 0.00 | 5.59 | 2.15 | -1.45 | -62.86% |
| Return on Equity | -49.9% | -55.6% | -37.3% | -33.7% | -42.90% |
| Total Debt | $219.38K | $193.71K | $167.32K | $140.20K | -42.63% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
